Braemar plc delivered a resilient FY25 performance, underpinned by a robust diversification strategy and disciplined cost management. Despite a 7% decline in revenue to £141.9 million, driven by softer tanker and dry cargo rates in H2, underlying operating profit margin was maintained at 12%, reflecting tight cost control and operational efficiencies. The Group's investment advisory division saw strong 18% growth, highlighting the effectiveness of its broader revenue mix. Net debt of £2.5 million at year-end was quickly reversed in line with Braemar's typical working capital cycle. A solid forward order book of $82.2 million underscores revenue visibility, while total shareholder returns were maintained through a £2 million share buyback and a revised final dividend of 2.5p. Looking ahead, Braemar has launched a refreshed strategic framework targeting £200m in revenue by FY30 and a 15% EBITDA margin, supported by continued investments in talent, digital infrastructure, and M&A opportunities. Regulatory tailwinds, an ageing global fleet, and increasing demand for decarbonised shipping solutions present significant growth opportunities. With global presence across 18 offices and a focus on operational excellence, Braemar remains well positioned to capitalise on shipping market dynamics, enhance margins, and deliver long-term shareholder value.

Impax Asset Management’s interim results for the six months to 31 March 2025 reflect a business navigating short-term headwinds while strengthening its long-term strategic position. Despite a challenging first half marked by continued outflows—most notably the loss of the St. James’s Place mandate—Impax reports a significant turnaround in investment performance, with over 70% of AUM outperforming benchmarks year-to-date. Revenue and EBITDA declined modestly, in line with reduced assets under management, while a disciplined cost reduction programme delivered £11m in run-rate savings, protecting margins (26.8%) amid falling income. Impax maintained a strong balance sheet, ending the period with £63.1m in capital surplus, and reaffirmed its commitment to shareholders through a rebased dividend of 4.0p and a £10m share buyback. Strategic growth priorities include scaling its fixed income offering—bolstered by the acquisition of Sky Harbor—and expanding private equity exposure in European renewable energy. Distribution capabilities were enhanced in Scandinavia, Canada, and emerging markets. With improving market conditions, strong institutional interest, and a return to benchmark outperformance, Impax expects net inflows to resume in FY2026. The firm remains focused on sustainable investing, EBITDA growth, and disciplined capital allocation, positioning itself as a global leader in the transition to a more sustainable economy.

React Group PLC (AIM:REAT) delivered a resilient H1 2025 performance, highlighting strong recurring revenues, expanding gross margins, and disciplined execution despite macroeconomic headwinds. Revenue rose 14% to £12.1m, driven by recurring contract wins across its four divisions—specialist cleaning, hygiene services, commercial window cleaning, and the newly acquired Aquaflow drainage solutions. Gross profit increased 35% to £3.9m, with gross margins expanding to 32%, aided by higher-margin services and operational efficiencies. EBITDA grew 12% to £1.43m, while free cash flow remained positive at £200k post-acquisition and strategic investment costs. Aquaflow, acquired in late 2024, contributed £2.8m revenue and £870k EBITDA in just five months, showcasing rapid integration, cross-sell synergies, and high recurring income. React’s platform continues to scale via Project Sparkle—its digital transformation initiative—unlocking future margin expansion and scalability in its LaddersFree division. With 85% of revenues recurring and a low customer churn rate under 2.5%, React remains well-positioned in the facilities management sector, offering essential, non-discretionary services nationwide. The group reaffirmed its ambition to achieve £5m annual free cash flow within three years, supported by a strong sales pipeline, ongoing contract renewals, and prudent capital allocation. Investors were reassured by management’s transparency on cost pass-throughs, capacity headroom, and a clear growth strategy focused on organic performance and long-term value creation.

Premier Miton Group PLC (LSE:PMI) reported resilient interim results for H1 2025, showcasing its strength as a diversified, actively managed asset manager. Despite continued market volatility, the group maintained a solid position with £10.2 billion in assets under management (AUM), growing to £10.4 billion post-period. Notably, 71% of funds have outperformed since inception or manager tenure, reinforcing Premier Miton’s high-conviction, alpha-generating investment approach. The firm delivered an adjusted profit before tax of £5.4 million and maintained a strong cash balance of £31.2 million. Strategic cost-saving measures identified £3 million in annual run-rate efficiencies, supporting long-term scalability and EBITDA margins. Growth was particularly strong in fixed income and absolute return strategies, with the flagship Strategic Bond and UK Select Funds delivering top-quartile performance. Premier Miton also expanded its offshore reach with fund launches in Dublin and new distribution channels in South Africa. The successful integration of the Tellworth acquisition and a healthy M&A pipeline highlight the company’s disciplined approach to scaling investment talent and enhancing product mix. With a robust balance sheet, high active share strategies, and continued demand for income and risk-managed solutions, Premier Miton is well positioned to drive future revenue growth and shareholder value in a changing investment landscape.

Atalaya Mining delivered a record-breaking Q1 2025, marking its strongest quarterly performance since 2021. The company achieved exceptional production and financial results, driven by higher copper grades (0.42%), minimal downtime, and continuous plant operation at a 60Mtpa rate. Revenues reached historic highs due to robust production volumes and favourable copper pricing, while EBITDA hit near-record levels. Improved cost control and a sharp drop in treatment charges—thanks to market dynamics and high-value spot sales—significantly lowered all-in sustaining costs, placing Atalaya among the lowest-cost copper producers globally. The company generated €26 million in free cash flow despite elevated inventory and strategic capex investments, ending the quarter with a strong balance sheet and €70–80 million in working capital. Operational enhancements and the commissioning of its solar facility further supported cost efficiency. Key milestones include FTSE 250 inclusion, progress on the Masa Valverde ramp, and the awarding of crucial environmental permits for San Dionisio and Touro, underscoring a stable and supportive regulatory environment. With conservative production guidance of 48–52kt copper unchanged, management expects to outperform cost guidance, indicating continued margin strength. Looking ahead, the company is poised for growth via high-grade satellite deposits, increased copper output from Masa Valverde, and long-term expansion through the Touro project. Atalaya remains focused on capital discipline, dividends, and potential value-accretive opportunities while maintaining strategic independence and exploring energy storage solutions.

ProBiotix Health delivered a strong performance in 2024, with revenue increasing 13% to £1.9 million and gross margins exceeding 50% for a second consecutive year. The company advanced its growth strategy, securing five new commercial partnerships across China, Korea, Greece, Mexico, and Ukraine, while doubling its customer base to 23 and expanding market presence to 14 countries. ProBiotix's proprietary LPLDL® probiotic strain—clinically supported and protected by 26 patents—remains central to its differentiated focus on cardio-metabolic health, including cholesterol and blood pressure reduction. A landmark 7-year exclusive distribution agreement with Kemin in China and a strategic partnership with Top Health in Korea are expected to drive significant revenue growth over the next five years. The company also saw Q1 2025 revenue surge 50% year-on-year, signaling continued momentum. Backed by a lean, asset-light business model and scalable supply chain, ProBiotix is well-positioned to meet its 2028 target of £10 million in revenue and 20% EBITDA margin. With a robust sales pipeline, expanding clinical validation, and no plans to raise additional funds, the outlook remains strong for sustained value creation.

Touchstone Exploration Inc. (LSE:TXP) delivered a comprehensive investor update highlighting its strategic transformation and near-term growth catalysts. The company reaffirmed its focus on onshore Trinidad operations, supported by robust infrastructure, a favourable regulatory environment, and a stable production base. Key financial results for Q1 include 4,300 BOE/d production and over 50 million BOE in 2P reserves, underpinning a 13-year reserve life. The recent $23M Central Block acquisition marks a pivotal shift, enabling access to higher-priced LNG markets and expanding production capacity to 72,000 BOE/d. The company is launching a fully funded "drill-to-fill" programme, aiming to convert significant reserves into cash flow through back-to-back well development. Despite historic drilling challenges and production declines at Cascadera, Touchstone has revamped its drilling strategy, optimised well designs, and brought in top-tier consultants to improve well performance and cost-efficiency. Management is targeting Q3–Q4 2025 for increased production volumes, supported by a continuous drilling schedule and upgraded infrastructure. Investors were also reassured on pricing: Central Block gas commands premium rates from day one, with further uplift expected post-2027. With a strong balance sheet, control over three gas plants, and an expanded acreage portfolio, Touchstone is well-positioned to deliver enhanced EBITDA, margin growth, and long-term shareholder value. The update reflects Touchstone’s strategic evolution from exploration to production-led cash generation, aligning its asset base with market opportunities and investor expectations.

Poolbeg Pharma PLC (AIM: POLB) delivered a compelling investor update outlining significant progress on its lead asset, POLB 001, a small molecule immunomodulator targeting cytokine release syndrome (CRS)—a serious and potentially fatal side effect of cancer immunotherapies. The company announced that the U.S. FDA granted POLB 001 Orphan Drug Designation for the prevention of T cell-engaging bispecific antibody-induced CRS, unlocking regulatory incentives, seven years of market exclusivity, and potential tax credits. Supported by a successful £4.865m fundraise and a £6.2m March-end cash position, Poolbeg is fully funded into 2027 and on track to initiate a Phase 2a trial in H2 2025, with interim data expected in H1 2026 and topline results by year-end. Preclinical data shows POLB 001 significantly reduces IL-6 and TNFα levels in validated CRS models, outperforming current reactive treatments. The drug addresses a critical unmet need in an estimated $10bn market, with no approved prophylactic therapies currently available. Importantly, large pharma partners have expressed strong interest and are expected to supply bispecific antibodies free of charge for the trial. POLB 001's oral administration also offers potential to reduce hospital burden and expand access to cancer therapies. Poolbeg is positioning itself as a leading innovator in supportive oncology care, with multiple near-term inflection points and strategic optionality driving investor appeal.

Inspiration Healthcare delivered a transformational FY25 marked by strategic restructuring, operational streamlining, and significant commercial wins, resulting in a strong H2 recovery. Despite flat headline revenue growth of 2%, the company posted a 25% uplift in H2 sales and returned to profitability, with EBITDA swinging from a £0.9m loss in H1 to a £1.1m profit in H2. Key growth drivers included a 29% rise in infusion therapy sales and 81% year-on-year growth at recently acquired ventilator specialist, Aēron. Two record orders—one in the Middle East and one from a global humanitarian organisation—enhanced the order book and support revenue visibility into FY26. Cost savings of £1.2m, a renewed focus on recurring revenues from consumables and services, and ongoing margin enhancement initiatives are expected to bolster future profitability. While regulatory pressures and margin dilution from product mix impacted gross margin (down to 43%), the outlook is positive with a strong sales pipeline, improving working capital, and targeted market expansion in Europe, North America, and Asia-Pacific. With innovative product launches, a sharpened focus on neonatal intensive care, and a back-to-basics operational approach, Inspiration is well-positioned to deliver sustained growth, improved margins, and shareholder value in FY26 and beyond.